iii) There can be concerns if physicians have to follow a large number of guidelines. This was the case in France with the RMO in France before their demise (discussed in Sermet et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Applied health economics and health policy. 2010;8:7-24 . Good to discuss how this was avoided in China iv) Trust in guidelines/ prescribing guidance is also important -with e.g. concerns if conflicts of interest (Shnier A et al. Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase. BMC health services research. 2016;16:383) . This is addressed in e.g. Stockholm, Sweden, with their prescribing guidance/ guidelines by having strong conflicts of interest statements, robust systems for selecting medicines in the guidance and comprehensive dissemination strategies. As a result, high adherence and trust in the guidance (Gustafsson LL et al. The 'wise list'-a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic & clinical pharmacology & toxicology. 2011; 108:224-33 Thank you -I enjoyed reading this paper to add to the literature on ways to improve guideline adherence -which is a very important topic for well accepted and unbiased guidelines (as pointed out). This includes good analysis of factors affecting guideline adherence, a good methodology and rationale for the chosen area, disease states, and compliance checks. In addition -the generation of good indicator. There was also a reasonable compliance with the CPs (averaging 57%) and good compliance with the KPIs (overall just under 70% -although some lower) when compared with other published studies -and elaborated on in pages 18/ 19. Good comments also about the organisational and motivational factors (Pages 19/20.
My comments are only minor. These include:
A) Introduction Page 7 i) Reference 2 appears to be a study protocol -has this been published yet?
Response: Yes, Reference 2 is a study protocol. We deleted Reference 2 and added other references according to your suggestion.
ii) What is the extent of the financial payment -good to insert details here as we know that appreciable payments can negatively impact on non-incentivised care as seen in the UK with the QoF targets and payments ( Response: Thank you for sharing the information with us. However, we did not collect detailed information about the financial payment in our study. Based on our knowledge of the program, the financial payment policies for CP implementation in China were determined by each hospital and were quite varied. As a result, it is not possible to include detailed information in the analyses. We added this as a study limitation.
iii) There can be concerns if physicians have to follow a large number of guidelines. Response: Because our study mainly focused on the effect of physician financial incentives on clinical pathway compliance, we did not collect the data related to the physicians' trust on guidelines and the hospital dissemination strategies. We added this limitation in the study. Response: Thank you for sharing this information with us. Nonetheless, we did not add this information in our paper. Because not only CP adherence but also other factors affect medical quality, it is possible that CP adherence alone may not be a good predictor in other cases.
